BR112012026545A2 - composições e métodos para tratar exacerbação de copd - Google Patents

composições e métodos para tratar exacerbação de copd

Info

Publication number
BR112012026545A2
BR112012026545A2 BR112012026545A BR112012026545A BR112012026545A2 BR 112012026545 A2 BR112012026545 A2 BR 112012026545A2 BR 112012026545 A BR112012026545 A BR 112012026545A BR 112012026545 A BR112012026545 A BR 112012026545A BR 112012026545 A2 BR112012026545 A2 BR 112012026545A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
treating copd
copd exacerbation
exacerbation
Prior art date
Application number
BR112012026545A
Other languages
English (en)
Portuguese (pt)
Inventor
Coyle Anthony
Finch Donna
Stampfli Martin
Original Assignee
Univ Mcmaster
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcmaster, Medimmune Ltd filed Critical Univ Mcmaster
Publication of BR112012026545A2 publication Critical patent/BR112012026545A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012026545A 2010-04-16 2011-04-18 composições e métodos para tratar exacerbação de copd BR112012026545A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US41610210P 2010-11-22 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (1)

Publication Number Publication Date
BR112012026545A2 true BR112012026545A2 (pt) 2019-09-24

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026545A BR112012026545A2 (pt) 2010-04-16 2011-04-18 composições e métodos para tratar exacerbação de copd

Country Status (11)

Country Link
US (1) US20130149312A1 (enExample)
EP (1) EP2558112A4 (enExample)
JP (1) JP2013525310A (enExample)
KR (1) KR20130086141A (enExample)
CN (1) CN102985100A (enExample)
AU (1) AU2011239402A1 (enExample)
BR (1) BR112012026545A2 (enExample)
CA (1) CA2796083A1 (enExample)
MX (1) MX2012012063A (enExample)
RU (1) RU2012148721A (enExample)
WO (1) WO2011130745A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
WO2015182121A1 (ja) * 2014-05-29 2015-12-03 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
US10286068B2 (en) 2015-04-15 2019-05-14 Ohio State Innovation Foundation Methods to improve induction of IgA antibodies by vaccines
EP3303444A1 (en) 2015-06-05 2018-04-11 The University of Rochester Shape-memory polymers and methods of making and use thereof
KR102208549B1 (ko) * 2019-05-16 2021-01-27 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
MX2022006636A (es) * 2019-12-02 2022-11-09 Altavant Sciences Gmbh Tratamiento de trastornos de las vías respiratorias bajas.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
NZ566539A (en) * 2002-09-06 2010-01-29 Medarex Inc Therapeutic human anti-IL-1R1 monoclonal antibody
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Also Published As

Publication number Publication date
CN102985100A (zh) 2013-03-20
AU2011239402A1 (en) 2012-10-25
EP2558112A1 (en) 2013-02-20
EP2558112A4 (en) 2014-06-18
KR20130086141A (ko) 2013-07-31
WO2011130745A1 (en) 2011-10-20
MX2012012063A (es) 2013-03-21
RU2012148721A (ru) 2014-05-27
US20130149312A1 (en) 2013-06-13
JP2013525310A (ja) 2013-06-20
CA2796083A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
PH12012502193A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
BR112012026545A2 (pt) composições e métodos para tratar exacerbação de copd
WO2012059598A3 (en) Methods of treating rheumatoid arthritis using il-17 antagonists
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
JP2014518898A5 (enExample)
UA111818C2 (uk) Антитіло проти csf-1r
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
HN2011001210A (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
CY1118014T1 (el) Aνti-il-23 αντισωματα
IL209277A (en) Antibodies and their antigen-binding segments that bind to the interleukin antibody and interleukin 6 and interleukin 6 receptor complex
MX375426B (es) Direccionamiento de antagonistas de citocinas.
EA201190116A1 (ru) Улучшенные полипептиды, вариабельные домены антител и антагонисты против tnfr1
BR112012024713A2 (pt) "anticorpo humanizado, anticorpo monoclonal humanizado ou fragmento de anticorpo, seus usos, polinucleotídeo isolado, e composição farmacêutica"
BRPI0918768A2 (pt) composições de anticorpo recombinante de anti-receptor do fator de crescimento epidérmico.
MX2011004751A (es) Miembros de union contra receptor 1 de la interleucina 1 (il-1r1).
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
PH12013500660B1 (en) Methods of treating psoriasis using il-17 antagonists
BR112014015111A2 (pt) composições e processos para anticorpos que se direcionam ao fator p
BR112013004012A2 (pt) anticorpos para o receptor de fator de crescimento epidérmico 3 (her3).
UA116873C2 (uk) Антитіло, яке зв'язується з ox40
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
BR112014013568A2 (pt) anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
MX347454B (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
BR112013033671A2 (pt) composições de polipeptídeo de fusão fc livre de arginina e métodos de uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.